Volume 9 Issue 1
Jan.  2018
Turn off MathJax
Article Contents
Kyoji Tsuchikama, Zhiqiang An. Antibody-drug conjugates: recent advances in conjugation and linker chemistries[J]. Protein&Cell, 2018, 9(1): 33-46. doi: 10.1007/s13238-016-0323-0
Citation: Kyoji Tsuchikama, Zhiqiang An. Antibody-drug conjugates: recent advances in conjugation and linker chemistries[J]. Protein&Cell, 2018, 9(1): 33-46. doi: 10.1007/s13238-016-0323-0

Antibody-drug conjugates: recent advances in conjugation and linker chemistries

doi: 10.1007/s13238-016-0323-0
Funds:

This work was supported in part by the Welch Foundation Grant AU00024 and the CPRIT grant RP150551.

  • Received Date: 2016-07-05
  • Rev Recd Date: 2016-08-06
  • The antibody-drug conjugate (ADC), a humanized or human monoclonal antibody conjugated with highly cytotoxic small molecules (payloads) through chemical linkers, is a novel therapeutic format and has great potential to make a paradigm shift in cancer chemotherapy. This new antibody-based molecular platform enables selective delivery of a potent cytotoxic payload to target cancer cells, resulting in improved efficacy, reduced systemic toxicity, and preferable pharmacokinetics (PK)/pharmacodynamics (PD) and biodistribution compared to traditional chemotherapy. Boosted by the successes of FDA-approved Adcetris® and Kadcyla®, this drug class has been rapidly growing along with about 60 ADCs currently in clinical trials. In this article, we briefly review molecular aspects of each component (the antibody, payload, and linker) of ADCs, and then mainly discuss traditional and new technologies of the conjugation and linker chemistries for successful construction of clinically effective ADCs. Current efforts in the conjugation and linker chemistries will provide greater insights into molecular design and strategies for clinically effective ADCs from medicinal chemistry and pharmacology standpoints. The development of site-specific conjugation methodologies for constructing homogeneous ADCs is an especially promising path to improving ADC design, which will open the way for novel cancer therapeutics.
  • loading
  • [1]
    An Z (2010) Monoclonal antibodies-a proven and rapidly expanding therapeutic modality for human diseases. Protein Cell 1:319-330
    [2]
    Axup JY, Bajjuri KM, Ritland M, Hutchins BM, Kim CH, Kazane SA, Halder R, Forsyth JS, Santidrian AF, Stafin K et al (2012) Synthesis of site-specific antibody-drug conjugates using unnatural amino acids. Proc Natl Acad Sci USA 109:16101-16106
    [3]
    Beerli RR, Hell T, Merkel AS, Grawunder U (2015) Sortase enzymemediated generation of site-specifically conjugated antibody drug conjugates with high in vitro and in vivo potency. PLoS ONE 10:e0131177
    [4]
    Behrens CR, Ha EH, Chinn LL, Bowers S, Probst G, Fitch-Bruhns M, Monteon J, Valdiosera A, Bermudez A, Liao-Chan S et al (2015) Antibody-drug conjugates (ADCs) derived from interchain cysteine cross-linking demonstrate improved homogeneity and other pharmacological properties over conventional heterogeneous ADCs. Mol Pharm 12:3986-3998
    [5]
    Bouchard H, Viskov C, Garcia-Echeverria C (2014) Antibody-drug conjugates-a new wave of cancer drugs. Bioorg Med Chem Lett 24:5357-5363
    [6]
    Bryant P, Pabst M, Badescu G, Bird M, McDowell W, Jamieson E, Swierkosz J, Jurlewicz K, Tommasi R, Henseleit K et al (2015) In vitro and in vivo evaluation of cysteine rebridged trastuzumab-MMAE antibody drug conjugates with defined drug-to-antibody ratios. Mol Pharm 12:1872-1879
    [7]
    Bryden F, Maruani A, Savoie H, Chudasama V, Smith MEB, Caddick S, Boyle RW (2014) Regioselective and stoichiometrically controlled conjugation of photodynamic sensitizers to a HER2 targeting antibody fragment. Bioconjugate Chem 25:611-617
    [8]
    Chari RVJ (2008) Targeted cancer therapy:conferring specificity to cytotoxic drugs. Acc Chem Res 41:98-107
    [9]
    Chari RVJ, Miller ML, Widdison WC (2014) Antibody-drug conjugates:an emerging concept in cancer therapy. Angew Chem Int Ed Engl 53:3796-3827
    [10]
    Chudasama V, Maruani A, Caddick S (2016) Recent advances in the construction of antibody-drug conjugates. Nat Chem 8:114-119
    [11]
    Damelin M, Zhong W, Myers J, Sapra P (2015) Evolving strategies for target selection for antibody-drug conjugates. Pharm Res 32:3494-3507
    [12]
    Dennler P, Chiotellis A, Fischer E, Brégeon D, Belmant C, Gauthier L, Lhospice F, Romagne F, Schibli R (2014) Transglutaminasebased chemo-enzymatic conjugation approach yields homogeneous antibody-drug conjugates. Bioconjugate Chem 25:569-578
    [13]
    DeVita VT, Chu E (2008) A history of cancer chemotherapy. Cancer Res 68:8643-8653
    [14]
    Diamantis N, Banerji U (2016) Antibody-drug conjugates-an emerging class of cancer treatment. Br J Cancer 114:362-367
    [15]
    Drake PM, Rabuka D (2015) An emerging playbook for antibodydrug conjugates:lessons from the laboratory and clinic suggest a strategy for improving efficacy and safety. Curr Opin Chem Biol 28:174-180
    [16]
    Dubowchik GM, Firestone RA, Padilla L, Willner D, Hofstead SJ, Mosure K, Knipe JO, Lasch SJ, Trail PA (2002) Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates:model studies of enzymatic drug release and antigen-specific in vitro anticancer activity.Bioconjugate Chem 13:855-869
    [17]
    Ehrlich P (1913) Address in pathology, ON CHEMIOTHERAPY:delivered before the seventeenth International Congress of Medicine. Br Med J 2:353-359
    [18]
    Finbloom DS, Abeles D, Rifai A, Plotz PH (1980) The specificity of uptake of model immune complexes and other protein aggregates by the murine reticuloendothelial system. J Immunol 125:1060-1065
    [19]
    Ford CH, Newman CE, Johnson JR, Woodhouse CS, Reeder TA, Rowland GF, Simmonds RG (1983) Localisation and toxicity study of a vindesine-anti-CEA conjugate in patients with advanced cancer. Br J Cancer 47:35-42
    [20]
    Gondi CS, Rao JS (2013) Cathepsin B as a cancer target. Expert Opin Ther Targets 17:281-291
    [21]
    Hartley JA (2011) The development of pyrrolobenzodiazepines as antitumour agents. Expert Opin Investig Drugs 20:733-744
    [22]
    Jain N, Smith SW, Ghone S, Tomczuk B (2015) Current ADC linker chemistry. Pharm Res 32:3526-3540
    [23]
    Jeger S, Zimmermann K, Blanc A, Grünberg J, Honer M, Hunziker P, Struthers H, Schibli R (2010) Site-specific and stoichiometric modification of antibodies by bacterial transglutaminase. Angew Chem Int Ed Engl 49:9995-9997
    [24]
    Junutula JR, Raab H, Clark S, Bhakta S, Leipold DD, Weir S, Chen Y, Simpson M, Tsai SP, Dennis MS et al (2008) Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotechnol 26:925-932
    [25]
    Kern JC, Cancilla M, Dooney D, Kwasnjuk K, Zhang R, Beaumont M, Figueroa I, Hsieh S, Liang L, Tomazela D et al (2016) Discovery of pyrophosphate diesters as tunable, soluble, and bioorthogonal linkers for site-specific antibody-drug conjugates. J Am Chem Soc 138:1430-1445
    [26]
    King HD, Dubowchik GM, Mastalerz H, Willner D, Hofstead SJ, Firestone RA, Lasch SJ, Trail PA (2002) Monoclonal antibody conjugates of doxorubicin prepared with branched peptide linkers:inhibition of aggregation by methoxytriethyleneglycol chains. J Med Chem 45:4336-4343
    [27]
    Kung Sutherland MS, Walter RB, Jeffrey SC, Burke PJ, Yu C, Kostner H, Stone I, Ryan MC, Sussman D, Lyon RP et al (2013) SGN-CD33A:a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drugresistant AML. Blood 122:1455-1463
    [28]
    Laguzza BC, Nichols CL, Briggs SL, Cullinan GJ, Johnson DA, Starling JJ, Baker AL, Bumol TF, Corvalan JR (1989) New antitumor monoclonal antibody-vinca conjugates LY203725 and related compounds:design, preparation, and representative in vivo activity. J Med Chem 32:548-555
    [29]
    Lazar AC, Wang L, Blättler WA, Amphlett G, Lambert JM, Zhang W (2005) Analysis of the composition of immunoconjugates using size-exclusion chromatography coupled to mass spectrometry. Rapid Commun Mass Spectrom 19:1806-1814
    [30]
    Lencer WI, Blumberg RS (2005) A passionate kiss, then run:exocytosis and recycling of IgG by FcRn. Trends Cell Biol 15:5-9
    [31]
    Linenberger ML, Hong T, Flowers D, Sievers EL, Gooley TA, Bennett JM, Berger MS, Leopold LH, Appelbaum FR, Bernstein ID (2001) Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin. Blood 98:988-994
    [32]
    LoRusso PM, Weiss D, Guardino E, Girish S, Sliwkowski MX (2011) Trastuzumab emtansine:a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer. Clin Cancer Res 17:6437-6447
    [33]
    Lyon RP, Bovee TD, Doronina SO, Burke PJ, Hunter JH, NeffLaFord HD, Jonas M, Anderson ME, Setter JR, Senter PD (2015) Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index. Nat Biotechnol 33:733-735
    [34]
    Madej MP, Coia G, Williams CC, Caine JM, Pearce LA, Attwood R, Bartone NA, Dolezal O, Nisbet RM, Nuttall SD et al (2012) Engineering of an anti-epidermal growth factor receptor antibody to single chain format and labeling by Sortase A-mediated protein ligation. Biotechnol Bioeng 109:1461-1470
    [35]
    Maruani A, Smith MEB, Miranda E, Chester KA, Chudasama V, Caddick S (2015) A plug-and-play approach to antibody-based therapeutics via a chemoselective dual click strategy. Nat Commun 6:6645
    [36]
    Mathe G, Loc TB, Bernard J (1958) Effect on mouse leukemia 1210 of a combination by diazo-reaction of amethopterin and gammaglobulins from hamsters inoculated with such leukemia by heterografts. C R Hebd Seances Acad Sci 246:1626-1628
    [37]
    McCombs JR, Owen SC (2015) Antibody drug conjugates:design and selection of linker, payload and conjugation chemistry. AAPS J 17:339-351
    [38]
    Mills BJ, Lang CA (1996) Differential distribution of free and bound glutathione and cyst(e)ine in human blood. Biochem Pharmacol 52:401-406
    [39]
    Mullard A (2013) Maturing antibody-drug conjugate pipeline hits 30. Nat Rev Drug Discov 12:329-332
    [40]
    Perez HL, Cardarelli PM, Deshpande S, Gangwar S (2014) Antibody-drug conjugates:current status and future directions. Drug Discov Today 19:869-881
    [41]
    Polson AG, Ho WY, Ramakrishnan V (2011) Investigational antibody-drug conjugates for hematological malignancies. Expert Opin Investig Drugs 20:75-85
    [42]
    Popp MWL, Antos JM, Ploegh HL (2009) Site-specific protein labeling via sortase-mediated transpeptidation. Curr Protoc Protein Sci. doi: 10.1002/0471140864.ps1503s56
    [43]
    Postow MA, Callahan MK, Wolchok JD (2015) Immune checkpoint blockade in cancer therapy. J Clin Oncol 33:1974-1982
    [44]
    Rudnick SI, Lou J, Shaller CC, Tang Y, Klein-Szanto AJP, Weiner LM, Marks JD, Adams GP (2011) Influence of affinity and antigen internalization on the uptake and penetration of Anti-HER2 antibodies in solid tumors. Cancer Res 71:2250-2259
    [45]
    Saito G, Swanson JA, Lee K-D (2003) Drug delivery strategy utilizing conjugation via reversible disulfide linkages:role and site of cellular reducing activities. Adv Drug Deliv Rev 55:199-215
    [46]
    Sedlacek HH, Seemann G, Hoffmann D, Czech J (1992) Antibodies as carriers of cytotoxicity. Contrib Oncol 43:1-145
    [47]
    Sievers EL, Larson RA, Stadtmauer EA, Estey E, Löwenberg B, Dombret H, Karanes C, Theobald M, Bennett JM, Sherman ML et al (2001) Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol 19:3244-3254
    [48]
    Strop P, Liu S-H, Dorywalska M, Delaria K, Dushin RG, Tran T-T, Ho W-H, Farias S, Casas MG, Abdiche Y et al (2013) Location matters:site of conjugation modulates stability and pharmacokinetics of antibody drug conjugates. Chem Biol 20:161-167
    [49]
    Swee LK, Guimaraes CP, Sehrawat S, Spooner E, Barrasa MI, Ploegh HL (2013) Sortase-mediated modification of αDEC205 affords optimization of antigen presentation and immunization against a set of viral epitopes. Proc Natl Acad Sci USA 110:1428-1433
    [50]
    Teicher BA, Chari RVJ (2011) Antibody conjugate therapeutics:challenges and potential. Clin Cancer Res 17:6389-6397
    [51]
    ten Cate B, Bremer E, de Bruyn M, Bijma T, Samplonius D, Schwemmlein M, Huls G, Fey G, Helfrich W (2009) A novel AMLselective TRAIL fusion protein that is superior to Gemtuzumab Ozogamicin in terms of in vitro selectivity, activity and stability. Leukemia 23:1389-1397
    [52]
    Tian F, Lu Y, Manibusan A, Sellers A, Tran H, Sun Y, Phuong T, Barnett R, Hehli B, Song F et al (2014) A general approach to site-specific antibody drug conjugates. Proc Natl Acad Sci. USA 111:1766-1771
    [53]
    Tolcher AW, Sugarman S, Gelmon KA, Cohen R, Saleh M, Isaacs C, Young L, Healey D, Onetto N, Slichenmyer W (1999) Randomized phase Ⅱ study of BR96-doxorubicin conjugate in patients with metastatic breast cancer. J Clin Oncol 17:478-484
    [54]
    van Geel R, Wijdeven MA, Heesbeen R, Verkade JMM, Wasiel AA, van Berkel SS, van Delft FL (2015) Chemoenzymatic conjugation of toxic payloads to the globally conserved n-glycan of native mAbs provides homogeneous and highly efficacious antibodydrug conjugates. Bioconjugate Chem 26:2233-2242
    [55]
    VanBrunt MP, Shanebeck K, Caldwell Z, Johnson J, Thompson P, Martin T, Dong H, Li G, Xu H, D'Hooge F et al (2015) Genetically encoded azide containing amino acid in mammalian cells enables site-specific antibody-drug conjugates using click cycloaddition chemistry. Bioconjugate Chem 26:2249-2260
    [56]
    Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, Pegram M, Oh D-Y, Diéras V, Guardino E et al (2012) Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 367:1783-1791
    [57]
    Vinogradova EV, Zhang C, Spokoyny AM, Pentelute BL, Buchwald SL (2015) Organometallic palladium reagents for cysteine bioconjugation. Nature 526:687-691
    [58]
    Widdison W, Wilhelm S, Veale K, Costoplus J, Jones G, Audette C, Leece B, Bartle L, Kovtun Y, Chari R (2015) Metabolites of antibody-maytansinoid conjugates:characteristics and in vitro potencies. Mol Pharm 12:1762-1773
    [59]
    Witte MD, Cragnolini JJ, Dougan SK, Yoder NC, Popp MW, Ploegh HL (2012) Preparation of unnatural N-to-N and C-to-C protein fusions. Proc Natl Acad Sci USA 109:11993-11998
    [60]
    Wu G, Fang Y-Z, Yang S, Lupton JR, Turner ND (2004) Glutathione metabolism and its implications for health. J Nutr 134:489-492
    [61]
    Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, Forero-Torres A (2010) Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 363:1812-1821
    [62]
    Zhao RY, Wilhelm SD, Audette C, Jones G, Leece BA, Lazar AC, Goldmacher VS, Singh R, Kovtun Y, Widdison WC et al (2011) Synthesis and evaluation of hydrophilic linkers for antibodymaytansinoid conjugates. J Med Chem 54:3606-3623
    [63]
    Zhou Q, Stefano JE, Manning C, Kyazike J, Chen B, Gianolio DA, Park A, Busch M, Bird J, Zheng X et al (2014) Site-specific antibody-drug conjugation through glycoengineering. Bioconjugate Chem 25:510-520
    [64]
    Zimmerman ES, Heibeck TH, Gill A, Li X, Murray CJ, Madlansacay MR, Tran C, Uter NT, Yin G, Rivers PJ et al (2014) Production of site-specific antibody-drug conjugates using optimized non-natural amino acids in a cell-free expression system. Bioconjugate Chem 25:351-361
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (74) PDF downloads(12018) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return